Core Viewpoint - The stock of Giant Bio (02367) has dropped over 5%, currently down 5.7% at HKD 54.6, with a trading volume of HKD 560 million. The company is set to hold a board meeting to approve its mid-year results for 2025, amid negative media coverage affecting its performance during the 618 shopping festival [1]. Group 1: Financial Performance - According to China Merchants Securities International, the GMV growth rate for May and June has slowed to a mid-single-digit percentage year-on-year due to negative media sentiment [1]. - The firm projects that the company will achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, primarily driven by sales growth of approximately 25% for Comfy and over 50% for Collgene [1]. - The target price for the stock remains unchanged at HKD 77.0 [1]. Group 2: Market Outlook - Caitong Securities believes that after the recovery of the data for Kefu Mei in July, sales are expected to gradually rebound in the second half of the year [1].
巨子生物跌超5% 中期业绩披露在即 此前负面舆论拖累618大促表现